● Recruiting

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Condition: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

PhasePhase 1/Phase 2

Planned participants210

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839（sc） for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Huijie Duan · +86 17721286337 · huijie.duan@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (2)

Chongqing University Cancer Hospital	Chongqing, Chongqing Municipality, China	Recruiting
West China Hospital of Sichuan University	Chengdu, Sichuan, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07059221